DUTCH Weight Control in Atrial Fibrillation Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 280 participants.

Also called NCT06184633

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 280 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06184633
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06184633. Randomized; triple masking; primary purpose treatment. Start 2024-07-21 (actual); primary completion 2027-04-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
DUTCH Weight Control in Atrial Fibrillation Study
Acronym
DUTCH-WAIST
Condition
Obesity
Condition
Weight Loss
Intervention (Drug)
Semaglutide 3.2 MG/ML
Intervention (Drug)
Placebo
Lead sponsor
Rijnstate Hospital (class: other)

Record details

Record id
cardio:ct-nct06184633
Content hash
cdefc81cb36ac2d5002f214d5b8c6aee168e5d0fe6a5cd457fe103dddeb5fb41